Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants

Trial Profile

A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Metablok (Primary)
  • Indications Acute kidney injury; Cancer metastases; Sepsis
  • Focus Adverse reactions
  • Sponsors Arch Biopartners
  • Most Recent Events

    • 11 Dec 2018 According to a Arch Biopartners media release, the company has formed a subsidiary named Arch Clinical Pty Ltd to conduct this trial. A human trial application process has been started with the Alfred Health Human Research Ethics Committee (HREC). A decision regarding trial approval is expected before February 2019.
    • 11 Dec 2018 Status changed from planning to not yet recruiting.
    • 29 Oct 2018 According to a Arch Biopartners media release, this trial is expected to begin in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top